{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:17:39Z","timestamp":1772637459673,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ctrv.2014.10.007","type":"journal-article","created":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T01:54:36Z","timestamp":1415411676000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies"],"prefix":"10.1016","volume":"41","author":[{"given":"J.","family":"Remon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lianes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.10.007_b0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CEJ.0b013e32834dbc56","article-title":"Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma","volume":"21","author":"La Vecchia","year":"2010","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ctrv.2014.10.007_b0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The worldwide pandemic of asbestos-related disease","volume":"34","author":"Stayner","year":"2013","journal-title":"Annu Rev Public Health"},{"issue":"P2.14-007","key":"10.1016\/j.ctrv.2014.10.007_b0015","article-title":"Global patterns in the incidence of malignant mesothelioma, 1988-2002, using data published by the international Agency for Research on Cancer (IARC)","volume":"8","author":"Soeberg","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1289\/ehp.1002845","article-title":"Global magnitude of reported and unreported mesothelioma","volume":"119","author":"Park","year":"2011","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.ctrv.2014.10.007_b0025","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiologic prospective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.ctrv.2014.10.007_b0030","unstructured":"www.iarc.fr\/en\/publications\/pdfs-online\/epi\/sp160\/ (Accessed on 18.06.14)."},{"key":"10.1016\/j.ctrv.2014.10.007_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-642-10862-4_2","article-title":"Epidemiology of mesothelioma and historical background","volume":"189","author":"Craighead","year":"2011","journal-title":"Rec Res Cancer Res"},{"key":"10.1016\/j.ctrv.2014.10.007_b0040","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ctrv.2014.10.007_b0045","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.athoracsur.2014.04.040","article-title":"Women with malignant pleural mesothelioma have a threefold better survival rate than men","volume":"98","author":"Taioli","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2014.10.007_b0050","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","article-title":"Advances in the systemic therapy of malignant pleural mesothelioma","volume":"5","author":"Fennell","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0055","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0060","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0075","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac. Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","article-title":"Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study","volume":"17","author":"Byrne","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0085","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600505","article-title":"A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma","volume":"87","author":"Nowak","year":"2002","journal-title":"Br J Cancer"},{"issue":"P1.14-013","key":"10.1016\/j.ctrv.2014.10.007_b0090","article-title":"The effectiveness and safety of platinum based pemetrexed and platinum based gemcitabine treatment in patients with malignant pleural mesothelioma","volume":"8","author":"Ak","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.lungcan.2008.09.008","article-title":"Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia","volume":"64","author":"Lee","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0100","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00280-014-2429-5","article-title":"A phase II trial of prolonged, continuous infusi\u00f3n of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesotelioma","volume":"73","author":"Arrieta","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0105","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01243894-200601000-00007","article-title":"Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma","volume":"1","author":"van den Bogaert","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0120","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0125","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/01243894-200607000-00002","article-title":"Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program","volume":"1","author":"J\u00e4nne","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0130","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/JTO.0b013e31817c73ec","article-title":"Single-agent pemetrexed for chemona\u00efve and pre-treated patients with malignant pleural mesothelioma: results of an international Expanded Access Program","volume":"3","author":"Taylor","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0140","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0145","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2014.10.007_b0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/path.3979","article-title":"BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma","volume":"227","author":"Busacca","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.lungcan.2014.05.006","article-title":"Efficacy of phase I trials in malignant pleural mesothelioma: description of a series of patients in a single institution","volume":"85","author":"Raphael","year":"2014","journal-title":"Lung Cancer"},{"issue":"suppl; abstract 7530","key":"10.1016\/j.ctrv.2014.10.007_b0165","article-title":"Next-generation sequencing in malignant pleural mesothelioma a retrospective study","volume":"32","author":"Scagliotti","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0170","first-page":"2589","article-title":"Status of Anaplastic Lymphoma Kinase (ALK) in malignant mesothelioma","volume":"34","author":"Veresano","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2014.10.007_b0175","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.10.007_b0180","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JTO.0b013e31829e7ef9","article-title":"Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations","volume":"8","author":"Zauderer","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ctrv.2014.10.007_b0190","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of BAP1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.10.007_b0195","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Landreville","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.10.007_b0200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0959-8049(11)70098-3","article-title":"VANTAGE 014: Vorinostat in patients with advanced malignant pleural mesothelioma who failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial","volume":"47","author":"Krug","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0205","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"28","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"issue":"suppl; abstract 3000a","key":"10.1016\/j.ctrv.2014.10.007_b0210","article-title":"Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in patients with advanced solid tumors","volume":"30","author":"Soria","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0215","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"issue":"suppl; abstract 7083","key":"10.1016\/j.ctrv.2014.10.007_b0220","article-title":"SWOG 0722: a phase II study of mTOR inhibitor everolimus (RAD 001) in malignant pleural mesothelioma","volume":"30","author":"Garland","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0225","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"issue":"MO09.01","key":"10.1016\/j.ctrv.2014.10.007_b0230","article-title":"Evaluation of tolerability and anti-tumor activity of GDC0980, an oral PI3K\/mTOR inhibitor, administrated to patients with advanced malignant pleural mesothelioma","volume":"8","author":"Dolly","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0235","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0240","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicenter, randomized phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0245","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0250","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicentre phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0255","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicentre, double-blind, placebo controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl; TPS7112a","key":"10.1016\/j.ctrv.2014.10.007_b0260","article-title":"IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II\/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma","volume":"30","author":"Zalcman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0265","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mdu098","article-title":"Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced non-squamous non-small cell lung cancer: updated survival analysis of the AVAPERL randomized phase III trial","volume":"25","author":"Barlesi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0270","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"issue":"P1.14-009","key":"10.1016\/j.ctrv.2014.10.007_b0275","article-title":"Biomarker results from a phase I study of cediranib in combination with cisplatin and pemetrexed in chemona\u00efve patients with malignant pleural mesothelioma (SWOG 0905)","volume":"8","author":"Fujmoto","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0280","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of The University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0290","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant pleural mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0295","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0300","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"Phase II study of intermitent sunitinib maleate as second-line therapy in progressive in malignant pleural mesotelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0305","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of vascular disrupting agent BNCP105P as second line chemotherapy for advanced malignant pleural mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"issue":"suppl; abstract 7076","key":"10.1016\/j.ctrv.2014.10.007_b0310","article-title":"NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM)","volume":"30","author":"Rossoni","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0315","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/JTO.0b013e3181839693","article-title":"Inhibition of Hsp90 leads to cell arrest and apoptosis in human malignant pleural mesothelioma","volume":"3","author":"Okamoto","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"suppl; abstract CRA 8007","key":"10.1016\/j.ctrv.2014.10.007_b0320","article-title":"A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)","volume":"31","author":"Ramalingam","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0325","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"suppl; abstract 7507","key":"10.1016\/j.ctrv.2014.10.007_b0330","first-page":"52","article-title":"Randomized trial of arginine deprivation with pegylated arginine deaminase in patients with malignant pleural mesothelioma","volume":"32","author":"Wojciech","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0335","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.seminoncol.2013.12.014","article-title":"Immune checkpoints blockade: the hope for immunotherapy as a treatment of lung cancer","volume":"41","author":"Brahmer","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0340","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000000059","article-title":"Emerging immunotherapies in the treatment of non-small cell lung cancer. The role of immune checkpoints inhibitors","author":"Langer","year":"2014","journal-title":"Am J Clin Oncol"},{"issue":"suppl; abstract 7589","key":"10.1016\/j.ctrv.2014.10.007_b0345","article-title":"T-Cell inflamed phenotype and PDL1 expression in malignant mesothelioma","volume":"32","author":"Kindler","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0350","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoide histology and poor prognosis","volume":"97","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0355","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesotelioma","author":"Cedres","year":"2014","journal-title":"ESMO"},{"key":"10.1016\/j.ctrv.2014.10.007_b0360","article-title":"Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer additional analysis from clinical study of the engineered antibody MPDL3280A (anti-PDL1)","author":"Soria","year":"2013","journal-title":"Eur Cancer Cong"},{"key":"10.1016\/j.ctrv.2014.10.007_b0365","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy resistant advanced malignant pleural mesothelioma: an open-label, single-arm, phase II trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"issue":"suppl; abstract 7531","key":"10.1016\/j.ctrv.2014.10.007_b0370","article-title":"A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients","volume":"32","author":"Calabr\u00f2","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0375","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"19","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.10.007_b0380","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"suppl; abstract 7030","key":"10.1016\/j.ctrv.2014.10.007_b0385","article-title":"Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: results of a multicenter phase II clinical trial","volume":"30","author":"Hassan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"O22.05","key":"10.1016\/j.ctrv.2014.10.007_b0390","article-title":"Exposure-response relationship of amatuximab in combination with pemetrexed and cisplatin in patients with unresectable pleural mesotelioma","volume":"8","author":"Maltzman","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"suppl; abstract 7532","key":"10.1016\/j.ctrv.2014.10.007_b0395","article-title":"Anti-mesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma","author":"Hassan","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.10.007_b0400","first-page":"5151","article-title":"Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P","volume":"32","author":"Zhang","year":"2012","journal-title":"Anticancer Res"},{"issue":"208","key":"10.1016\/j.ctrv.2014.10.007_b0405","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2014.10.007_b0410","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.10.007_b0415","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ctrv.2014.10.007_b0420","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/mt.2010.159","article-title":"Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms","volume":"18","author":"Fridlender","year":"2010","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2014.10.007_b0425","doi-asserted-by":"crossref","first-page":"e26218","DOI":"10.4161\/onci.26218","article-title":"Immunological effects of the TGF\u03b2-blocking antibody GC1008 in malignant pleural mesothelioma patients","volume":"2","author":"Stevenson","year":"2013","journal-title":"Oncoimmunology"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721400173X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721400173X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T01:08:36Z","timestamp":1566004116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721400173X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S030573721400173X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.10.007","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}